{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022696","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.456571+00:00","generated_at":"2026-06-22T05:52:17.560009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"HCW Biologics Q3: $1.8M revenue, $3.9M net loss; cash $35.9M funds through 2023","bullets":["Cash and investments $35.9M as of Sep 30; sufficient to fund operations through end of 2023.","Q3 2022 revenue of $1.8M from clinical material sales to licensee Wugen; no revenue in prior year.","Net loss $3.9M in Q3 2022 vs $4.1M in Q3 2021; R&D flat at $2.7M, G&A up 23% to $1.7M.","Three clinical sites activated for HCW9218 Phase 1b/2 in advanced pancreatic cancer; first patient dosed Oct 17.","Purchased new HQ in Miramar, FL for ~$10M, financed with $6.5M loan at 5.75% interest."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022696","json":"https://secwatch.observer/filing/0000950170-22-022696.json","markdown":"https://secwatch.observer/filing/0000950170-22-022696.md","text":"https://secwatch.observer/filing/0000950170-22-022696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017022022696/0000950170-22-022696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017022022696/hcwb-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:52:17.560009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f148dc78a094a13002dde063d3dff88e43c9fd7","claim":"HCW Biologics Inc. reported third quarter ended September 30, 2022 results: revenue $1.8 million.","evidence_excerpt":"securities. The Company estimates that the current cash balance is sufficient to fund operations and capital expenditures through the end of 2023. • Revenues: Revenues were $1.8 million for the three-month period ended September 30, 2022, and there were no revenues in the three-month period ended September 30, 2021. Revenues were $5.4 million for the nine-month","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017022022696/0000950170-22-022696-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}